MetaVia Inc. reported its financial results for the second quarter of 2025, revealing a significant reduction in both operating expenses and net losses compared to the same period in 2024. The company recorded total operating expenses of $4.3 million for the three months ended June 30, 2025, a decrease of 57.3% from $10.1 million in the prior year. This decline was primarily driven by a substantial reduction in research and development (R&D) expenses, which fell to $2.3 million from $8.1 million year-over-year. The net loss for the quarter was $4.0 million, or $0.26 per share, compared to a net loss of $10.0 million, or $1.85 per share, in the same quarter of 2024.
For the six months ended June 30, 2025, MetaVia's total operating expenses were $8.2 million, down 51.7% from $17.0 million in the first half of 2024. R&D expenses for this period also decreased significantly to $4.6 million from $13.0 million, reflecting reduced clinical trial activities for its product candidates DA-1241 and DA-1726. The company reported a net loss of $7.7 million, or $0.60 per share, compared to a net loss of $16.8 million, or $3.19 per share, for the same period in 2024.
In terms of strategic developments, MetaVia completed a private placement in May 2025, raising gross proceeds of $10.0 million from the sale of common stock and pre-funded warrants to Dong-A ST and its affiliate. This funding is expected to support ongoing clinical trials, including the Phase 2a trial for DA-1241 and the Phase 1 trial for DA-1726. The company also reported an increase in its cash position, ending the quarter with $17.6 million, up from $16.0 million at the end of 2024.
Operationally, MetaVia has been focusing on its two primary product candidates, DA-1241 and DA-1726, which target metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company is currently finalizing a Clinical Study Report for the Phase 2a trial of DA-1241 and has initiated a higher-dose cohort in the Phase 1 trial for DA-1726. As of June 30, 2025, MetaVia had 24.2 million shares of common stock outstanding, reflecting the impact of recent equity financing activities.
Looking ahead, MetaVia anticipates continued net losses and negative cash flows as it progresses through its clinical trials. The company has expressed confidence that its existing cash will fund operations into 2026, but it acknowledges the need for additional financing to support ongoing and future development efforts. The management has indicated that they will explore various funding avenues, including equity offerings and collaborations, to ensure the sustainability of their operations.
About MetaVia Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.